Search Reports:
  Search
spacer
MORE INFORMATIONarrow
Not sure this is the report that you need? Have questions about the report before purchasing? We're here to help!
HOW TO ORDERarrow
Ordering reports couldn't be easier. Select the license for your needs, click Order Now, and complete our streamlined checkout process. We accept major credit cards, wire/bank transfers, and checks.

MC, Visa, AMEX, Diners, Discovery, JCB
MORE OPTIONSarrow
ABOUT THE PUBLISHERarrow
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.

Kenya Pharmaceuticals & Healthcare Report Q2 2014

Published by Business Monitor International on Jan 30, 2014 - 111 pages
PDF - Download Now with 3 Quarterly Updates format - Download Now
License Options Question

Report Abstract Table of Contents Request Sample
It is vital that companies that are looking to sell non-communicable disease therapeutics work alongside the public sector and focus on physician education and patient awareness in a market that has traditionally focussed on infectious diseases such as malaria, tuberculosis and HIV. Besides challenges related to diagnosis, care and treatment, there is a lack of understanding and knowledge about diseases such as diabetes and cardiovascular disease among healthcare professionals and the general population, and a perception that such diseases are not as critical as other diseases affecting the country.

Headline Expenditure Projections:

It is vital that companies that are looking to sell non-communicable disease therapeutics work alongside the public sector and focus on physician education and patient awareness in a market that has traditionally focussed on infectious diseases such as malaria, tuberculosis and HIV. Besides challenges related to diagnosis, care and treatment, there is a lack of understanding and knowledge about diseases such as diabetes and cardiovascular disease among healthcare professionals and the general population, and a perception that such diseases are not as critical as other diseases affecting the country.

Headline Expenditure Projections
  • Pharmaceuticals: KES55.29bn (US$642mn) in 2013 to KES64.40bn (US$740mn) in 2014; 16.5% growth in local currency terms and 15.3% in US dollar terms.
  • Healthcare: KES178.19bn (US$2.07bn) in 2013 to KES202.68bn (US$2.33bn) in 2014; 13.7% growth in local currency terms and 12.6% in US dollar terms.
Risk/Reward Rating: In BMI's Q214 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), Kenya is 20th in the Middle East and Africa (MEA). A large counterfeiting industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers more commercial promise and a more stable overall business environment.

Key Trends And Developments

In October 2013, German pharmaceutical company Merck KGaA set up an office in Nairobi, Kenya, aiming to increase the presence of its products in the East African pharmaceutical market. In November 2013, the Kenyan Health Sector Services Fund (HSSF) disbursed KES1.9bn (US$0.02bn) to dispensaries and health centres in Kenya. According to public health specialist Rael Mutai, county governments should be responsible for planning and budgeting funds for the successful operation of healthcare facilities. She added that the funds disbursed by the government should be considered conditional grants.

BMI Economic View: Below-expectation GDP expansion in the second half of 2013 has not led us to adjust our growth forecasts for 2014, and we still see Kenya's economy expanding by 6.1%. The country's It is vital that companies that are looking to sell non-communicable disease therapeutics work alongside the public sector and focus on physician education and patient awareness in a market that has traditionally focussed on infectious diseases such as malaria, tuberculosis and HIV. Besides challenges related to diagnosis, care and treatment, there is a lack of understanding and knowledge about diseases such as diabetes and cardiovascular disease among healthcare professionals and the general population, and a perception that such diseases are not as critical as other diseases affecting the country.

Headline Expenditure Projections
  • Pharmaceuticals: KES55.29bn (US$642mn) in 2013 to KES64.40bn (US$740mn) in 2014; 16.5% growth in local currency terms and 15.3% in US dollar terms.
  • Healthcare: KES178.19bn (US$2.07bn) in 2013 to KES202.68bn (US$2.33bn) in 2014; 13.7% growth in local currency terms and 12.6% in US dollar terms.
Risk/Reward Rating: In BMI's Q214 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), Kenya is 20th in the Middle East and Africa (MEA). A large counterfeiting industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers more commercial promise and a more stable overall business environment.

Key Trends And Developments

In October 2013, German pharmaceutical company Merck KGaA set up an office in Nairobi, Kenya, aiming to increase the presence of its products in the East African pharmaceutical market. In November 2013, the Kenyan Health Sector Services Fund (HSSF) disbursed KES1.9bn (US$0.02bn) to dispensaries and health centres in Kenya. According to public health specialist Rael Mutai, county governments should be responsible for planning and budgeting funds for the successful operation of healthcare facilities. She added that the funds disbursed by the government should be considered conditional grants.

BMI Economic View: Below-expectation GDP expansion in the second half of 2013 has not led us to adjust our growth forecasts for 2014, and we still see Kenya's economy expanding by 6.1%. The country's economic acceleration will gain momentum over the year, and we believe that growth will stabilise around 6.0% over the duration of our 2014-2018 forecast period.

BMI Political View: A lack of valid evidence has led the International Criminal Court to postpone its prosecution of Kenyan President Uhuru Kenyatta, and we doubt that the controversial trial will be restarted in 2014. Prosecutors allege that their witnesses are being deterred from testifying by a campaign of intimidation, a charge that the president's supporters deny. The trial's collapse would prevent a political clash between the ICC and African states that accuse it of bias.






Copyright © 2014 Fast Market Research, Inc.